Melanoma in children and adolescents: Distinct biology,evolving therapies,and unmet needs

Indini A Didonè F Massi D , et al. Incidence and prognosis of cutaneous melanoma in European adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results. Eur J Cancer 2024; 213: 115079.

Ferrari A Bisogno G de Salvo GL , et al. The challenge of very rare tumours in childhood: the Italian TREP project. Eur J Cancer 2007; 43: 654–659.

Bahrami A Barnhill RL. Pathology and genomics of pediatric melanoma: A critical reexamination and new insights. Pediatr Blood Cancer 2018; 65: 10.1002/pbc.26792.

Ferrari A Bisogno G Cecchetto G , et al. Cutaneous melanoma in children and adolescents: the Italian rare tumors in pediatric age project experience. J Pediatr 2014; 164: 376-82.e1-2.

Gershenwald JE Scolyer RA Hess KR , et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 472-492.

Jafarian F Powell J Kokta V , et al. Malignant melanoma in childhood and adolescence: report of 13 cases. J Am Acad Dermatol 2005; 53: 816-822.

Livestro DP Kaine EM Michaelson JS , et al. Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer 2007; 110: 614-624.

Lorimer PD White RL Walsh K , et al. Pediatric and adolescent melanoma: A National Cancer Data Base Update. Ann Surg Oncol 2016; 23: 4058-4066.

Mandalà M Ferrari A Brecht IB , et al. Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study). Eur J Cancer 2024; 211: 114305.

Indini A Brecht I Del Vecchio M , et al. Cutaneous melanoma in adolescents and young adults. Pediatr Blood Cancer 2018; 65: e27292.

Wolchok JD Chiarion-Sileni V Rutkowski P , et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. Epub ahead of print 15 September 2024. doi: 10.1056/NEJMoa2407417.

Long GV Carlino MS McNeil C , et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol 2024; 35: 1191-1199.

Robert C Grob JJ Stroyakovskiy D , et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019; 381: 626-636.

Schadendorf D Dummer R Flaherty KT , et al. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. Eur J Cancer 2024; 204: 114073.

Long GV Hauschild A Santinami M , et al. Final results for adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 2024; 391: 1709-1720.

Eggermont AM Kicinski M Blank CU , et al. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial. Eur J Cancer 2024; 211: 114327.

Larkin J Del Vecchio M Mandalá M , et al. Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res 2023; 29: 3352-3361.

Luke JJ Rutkowski P Queirolo P , et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 2022; 399: 1718-1729.

Kirkwood JM Del Vecchio M Weber J , et al. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med 2023; 29: 2835-2843.

Chisholm JC Suvada J Dunkel IJ , et al. BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma. Pediatr Blood Cancer 2018; 65: e26947.

Geoerger B Bergeron C Gore L , et al. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer 2017; 86: 358-363.

Weber JS Schadendorf D Del Vecchio M , et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol 2023; 41: 517-527.

Weber J Mandala M Del Vecchio M , et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; 377: 1824-1835.

Geoerger B Kang HJ Yalon-Oren M , et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol 2020; 21: 121-133.

Brecht IB De Paoli A Bisogno G , et al. Pediatric patients with cutaneous melanoma: A European study. Pediatr Blood Cancer 2018; 65: e26974.

Bowden A Zambito J El-Feghaly J , et al. Adjuvant immune checkpoint inhibitor therapy may benefit pediatric patients with stage III melanoma and sentinel lymph node positivity: a case series. Pediatr Hematol Oncol 2024; 41: 389-398.

Chiaravalli S Indini A Del Vecchio M , et al. Dabrafenib and trametinib for the treatment of pediatric and adolescent melanoma: single center experience data from the Italian compassionate use. Pediatr Blood Cancer 2025; 72: e31644.

European Medicines Agency (EMA). Opdivo (nivolumab) – Summary of Product Characteristics (SmPC), https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf (accessed 5 March 2025).

European Medicines Agency (EMA). Keytruda (pembrolizumab) – Summary of Product Characteristics (SmPC), https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf (accessed 5 March 2025).

European Medicines Agency (EMA). Tafinlar (dabrafenib) – Summary of Product Characteristics (SmPC), https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf (accessed 5 March 2025).

European Medicines Agency (EMA). Mekinist (trametinib) – Summary of Product Characteristics (SmPC), https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf (accessed 5 March 2025).

European Medicines Agency (EMA). Braftovi (encorafenib) – Summary of Product Characteristics (SmPC), https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf (accessed 5 March 2025).

European Medicines Agency (EMA). Mektovi (binimetinib) – Summary of Product Characteristics (SmPC), https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf (accessed 5 March 2025).

Craft AW Pearson ADJ . Three decades of chemotherapy for childhood cancer e from cure “at any cost” to cure “at least cost”. Cancer Surv 1990; 8: 605e29.

EMA. 5-year report to the European Commission. General report on the experience acquired as a result of the application of the Paediatric Regulation, 2013, http://ec.europa.eu/health/files/paediatrics/2012-09_paediatric_report-annex1-2_en.pdf.

Vassal G Rousseau R Blanc P , et al. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. Eur J Cancer 2015; 51: 218-224.

Pearson AD Herold R Rousseau R , et al. Implementation of mechanism of action biology-driven early drug development for children with cancer. Eur J Cancer 2016; 62: 124-131.

Bautista F Paci A Minard-Colin V , et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer 2014; 61: 1101e3.

Kieran MW Geoerger B Dunkel IJ , et al. A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors. Clin Cancer Res 2019; 25: 7294-7302.

Ferrari A Bernasconi A Sironi G , et al. Where are adolescents with cutaneous melanoma treated? An Italian nationwide study on referrals based on hospital discharge records. Pediatr Blood Cancer 2021; 68: e28566.

Brecht IB De Paoli A Bisogno G , et al. Pediatric patients with cutaneous melanoma: A European study. Pediatr Blood Cancer 2018; 65: e26974.

Bisogno G Ferrari A Bien E , et al. Rare cancers in children - The EXPeRT Initiative: a report from the European Cooperative Study Group on Pediatric Rare Tumors. Klin Padiatr 2012; 224: 416-420.

Ferrari A Lopez Almaraz R Reguerre Y , et al. Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatr Blood Cancer 2021; 68: e28992.

MELCAYA Consortium. MelCAYA: Melanoma Cancer in Children, Adolescents and Young Adults. Available at: https://www.melcaya.eu/ (accessed 4 January 2025).

Bozovic Spasojevic I Ferrari A De Munter J , et al. Have we made progress in taking care of adolescents and young adults with cancer? Results of a European multi-professional survey. Tumori 2023; 109: 546-554.

Casali PG Antoine-Poirel H Berrocoso S , et al. Health networking on cancer in the European Union: a ‘green paper’ by the EU Joint Action on Networks of Expertise (JANE). ESMO Open 2025; 10: 104126.